Home/Pipeline/ABO-504

ABO-504

Stargardt Disease

PreclinicalActive

Key Facts

Indication

Stargardt Disease

Phase

Preclinical

Status

Active

Company

Abeona Therapeutics

About Abeona Therapeutics

Abeona Therapeutics has successfully transitioned to a commercial-stage company with the launch of ZEVASKYN®, while advancing a pipeline of novel gene therapies for rare diseases with high unmet need. Its strategy is built on a proprietary AIM™ vector platform designed for enhanced delivery and efficacy, and is vertically integrated with internal manufacturing capabilities. The company is focused on inherited retinal diseases and neurological disorders, with key partnered programs in Sanfilippo Syndrome and Rett Syndrome. Abeona's mission is to deliver transformative, one-time treatments, aiming to make cures the new standard of care.

View full company profile

Therapeutic Areas

Inherited Retinal Diseases Neurological Disorders

Other Stargardt Disease Drugs

Drug	Company	Phase	Status
KIO-301	Kiora Pharmaceuticals	Preclinical	Active
EIR-0205	EIR Biopharma	Preclinical	Active
Emixustat HCl	Kubota Vision	Phase 3	Active
Gildeuretinol (ALK-001)	Alkeus Pharmaceuticals	Phase 3	Active
MCO-010	Nanoscope Therapeutics	Phase 2	Active
SB-007	SpliceBio	Phase 1/2	Active
LBS-008	Lin BioScience	Phase 3	Active
OCU410ST	Ocugen	Phase 2/3	Active